News

Becker's Hospital Review2d
FDA approves Dupixent as first chronic spontaneous urticaria therapy in over a decade
The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...
STAT2d
FDA approves blockbuster Dupixent for chronic hives
The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...
Zacks Investment Research on MSN2d
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...
Fierce Pharma5d
Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition
On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...
STAT2d
Pharmalittle: We’re reading about a Novo challenge to Medicare talks, a scuttled FDA office, and more
Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...
Contract Pharma2d
FDA Approves Dupixent in the U.S. for Chronic Spontaneous Urticaria
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) to treat adults and ...
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...
Medical Dialogues2d
FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...
PipelineReview.com4d
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...